TNX-1300 for Cocaine Intoxication
(CATALYST Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you receive anti-hypertensive medication in the emergency department before joining the study, you cannot participate.
Who Is on the Research Team?
Gregory Sullivan, MD
Principal Investigator
Tonix Pharmaceuticals
Are You a Good Fit for This Trial?
This trial is for males aged 18-64 who've used cocaine and are now in the emergency department with acute intoxication. They must be able to consent, have certain blood pressure levels, and a specific severity of symptoms. Those with mixed drug use may still qualify but it's up to the doctor's judgment.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single IV injection of TNX-1300 or placebo with usual care for acute cocaine intoxication
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of blood pressure and ECG
What Are the Treatments Tested in This Trial?
Interventions
- TNX-1300
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tonix Pharmaceuticals, Inc.
Lead Sponsor
Premier
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator